These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Aihara Y; Miyamae T; Ito S; Kobayashi S; Imagawa T; Mori M; Ibe M; Mitsuda T; Yokota S Pediatr Int; 2002 Apr; 44(2):199-204. PubMed ID: 11896887 [TBL] [Abstract][Full Text] [Related]
3. [Assessment of pharmacological correction in the treatment of patients with systemic lupus erythematosus]. Sultanova TZh Lik Sprava; 2009; (7-8):86-9. PubMed ID: 20455456 [TBL] [Abstract][Full Text] [Related]
5. Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus. Lavalle-Graef A; Villegas-Acosta L; Lavalle C Arch Med Res; 2004; 35(5):421-7. PubMed ID: 15610913 [TBL] [Abstract][Full Text] [Related]
6. Effective treatment with cyclosporine A of a child with systemic lupus erythematosus resistant to cyclophosphamide pulse therapy. Suzuki K; Tanaka H; Tsugawa K; Ito E Tohoku J Exp Med; 2006 Apr; 208(4):355-9. PubMed ID: 16565599 [TBL] [Abstract][Full Text] [Related]
7. Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Chan YK; Li EK; Tam LS; Chow LT; Ng HK Scand J Rheumatol; 2003; 32(5):306-8. PubMed ID: 14690145 [TBL] [Abstract][Full Text] [Related]
8. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. Vasquez S; Kavanaugh AF; Schneider NR; Wacholtz MC; Lipsky PE J Rheumatol; 1992 Oct; 19(10):1625-7. PubMed ID: 1464880 [TBL] [Abstract][Full Text] [Related]
9. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Godeau B; Cormier C; Menkes CJ Ann Rheum Dis; 1991 Dec; 50(12):956-8. PubMed ID: 1768170 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157 [TBL] [Abstract][Full Text] [Related]
12. Active idiopathic Systemic Lupus Erythematosus in a 94-year-old woman necessitating immunosuppressive therapy. Madge SN; Donegan C Age Ageing; 2002 Nov; 31(6):489-90. PubMed ID: 12446306 [No Abstract] [Full Text] [Related]
13. Current concepts in immunosuppressive drug therapy of systemic lupus erythematosus. Lehman TJ J Rheumatol Suppl; 1992 Apr; 33():20-2. PubMed ID: 1593597 [TBL] [Abstract][Full Text] [Related]
14. [Multicenter cooperative study of immunosuppressive therapy of systemic lupus erythematosus--a report of Therapy Research Division of Research Committee for Autoimmune Diseases, the Ministry of Health and Welfare]. Ichikawa Y; Tanaka H; Hirose S; Yokohari R; Tsunematsu T Ryumachi; 1988 Aug; 28(4):230-9. PubMed ID: 3055347 [No Abstract] [Full Text] [Related]
16. High-dose intravenous cyclophosphamide therapy in severe SLE. D'Cruz D Lupus; 2002; 11(7):403-4. PubMed ID: 12195779 [No Abstract] [Full Text] [Related]
17. [Recommendations for immunosuppressive therapy in systemic lupus erythematosus]. Deicher H Monatsschr Kinderheilkd (1902); 1972 Jun; 120(6):249-51. PubMed ID: 4115641 [No Abstract] [Full Text] [Related]
18. Urticarial vasculitis in systemic lupus erythematosus: fair response to prednisolone/dapsone and persistent hypocomplementemia. Nishijima C; Hatta N; Inaoki M; Sakai H; Takehara K Eur J Dermatol; 1999; 9(1):54-6. PubMed ID: 9920991 [TBL] [Abstract][Full Text] [Related]
19. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice. Hahn BH; Knotts L; Ng M; Hamilton TR Arthritis Rheum; 1975; 18(2):145-52. PubMed ID: 1131283 [TBL] [Abstract][Full Text] [Related]